📊 CGEM Key Takeaways
Investment Thesis
Cullinan Therapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with zero commercial revenue and operating losses of $241.6M. While the company maintains a strong balance sheet with $88.3M in cash and minimal debt, the substantial negative operating cash flow of $175.8M indicates unsustainable burn rate that will require either successful clinical trials, partnerships, or significant capital raises.
CGEM Strengths
- Strong liquidity position with $88.3M cash and 10.25x current ratio
- Minimal debt burden with 0.00x debt-to-equity ratio
- Substantial stockholders equity of $408.7M provides runway and capital flexibility
- Active insider engagement with 22 Form 4 filings in last 90 days
CGEM Risks
- Zero revenue with -100% YoY change indicates pre-commercial stage with no product sales
- Massive operating losses of $241.6M annually with negative operating margin
- Critical cash burn rate of $175.8M in operating cash flow threatening financial viability within 6 months at current burn
- Negative ROE of -53.8% and ROA of -49.0% reflecting value destruction
- Dilutive EPS of -$2.30 with -255% YoY deterioration indicates shareholder value erosion
Key Metrics to Watch
- Quarterly cash burn rate and cash runway until funding required
- Clinical trial progress and regulatory milestones for pipeline programs
- Operating cash flow trajectory and path to potential commercialization
- Capital structure changes and potential dilution from future financing
CGEM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.25x current ratio provides a solid financial cushion.
CGEM Profitability Ratios
CGEM vs Healthcare Sector
How Cullinan Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CGEM Balance Sheet & Liquidity
CGEM 5-Year Financial Trend
5-Year Trend Summary: Cullinan Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $2.38 reflects profitable operations.
CGEM Growth Metrics (YoY)
CGEM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | $1.4M | $-0.40 |
| Q2 2022 | N/A | $1.4M | $-0.36 |
| Q1 2022 | N/A | -$70.0K | N/A |
| Q3 2021 | $18.9M | $1.4M | N/A |
| Q2 2021 | $18.9M | $1.4M | N/A |
| Q1 2021 | $18.9M | -$70.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CGEM Capital Allocation
CGEM SEC Filings
Access official SEC EDGAR filings for Cullinan Therapeutics, Inc. (CIK: 0001789972)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGEM
What is the AI rating for CGEM?
Cullinan Therapeutics, Inc. (CGEM) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGEM's key strengths?
Strong liquidity position with $88.3M cash and 10.25x current ratio. Minimal debt burden with 0.00x debt-to-equity ratio.
What are the risks of investing in CGEM?
Zero revenue with -100% YoY change indicates pre-commercial stage with no product sales. Massive operating losses of $241.6M annually with negative operating margin.
What is CGEM's revenue and growth?
Cullinan Therapeutics, Inc. reported revenue of $0.0.
Does CGEM pay dividends?
Cullinan Therapeutics, Inc. does not currently pay dividends.
Where can I find CGEM SEC filings?
Official SEC filings for Cullinan Therapeutics, Inc. (CIK: 0001789972) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGEM's EPS?
Cullinan Therapeutics, Inc. has a diluted EPS of $-2.30.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.